Fierce Healthcare February 10, 2023
The Department of Health and Human Services laid out the first guidance for drugmakers on a new rebate program that requires companies to issue rebates back to Medicare if prices for Parts B and D drugs go past inflation. (malerapaso/Getty Images)
The Biden administration rolled out new guidance to drugmakers for meeting a new requirement to dole out rebates if their prices on Medicare Parts B and D go above inflation.
The guidance, released Thursday by the Department of Health and Human Services (HHS), implements a key part of the Inflation Reduction Act passed last year. Drug companies had to start paying rebates for raising prices past inflation back in January, with the amounts going back to Medicare.
...Today's Sponsors
Today's Sponsor